Study shows Oxford T-Spot.TB test is better than TST
Oxford TB test in CDC guidelines
KP Ventures invests in Baxano
KP Ventures invests in Predictive Biosciences
KP Ventures invests in Agile Therapeutics
AcelRx develops pain mgmt system for cancer
The Economist Highlights the KP Model
Accumetrics announces completion of GRAVITAS trial enrollment
KP Ventures invests in Hemosphere
Oxford Immunotec signs T cell contract with Scancell
HeRO® device improves quality of life for kidney patients
KP Ventures invests in Pulmonx
KP ranked 5th most innovative health care company
KP works with Michelle Obama to address childhood obesity
Kim Blickenstaff joins Predictive Bio's Board
CHF Solutions acquired by Gambro
Proteus announces sensor-based agreement
Predictive Bio announces ODL acquisition
KP and VA share electronic health information
KP Ventures invests in Celula
Predictive Biosciencies presents diagnostic assay at SUO
Henry J. Kaiser inducted into CA Hall of Fame
KP medicare plan ranked no. 1 in nation
Predictive Biosciencies announces publication of pilot study
AcelRx announces results from ARX-03 study
ValenTx Inc announces treatment of morbid obesity at ACSCC
Accumetrics announces $16.5M capital financing
Arcxis announces launch of ArcPure
KP Ventures invests in AtheroMed
Inverness acquires Free & Clear
Radianse and Hill-Rom announce partnering agreement
Avivia health records help cardiac patients
KP Ventures invests in Transcend Medical
Proteus tests a wireless sensor monitor for patients
Kaiser Permanente honored for combatting obesity
Calypso study shows potential for treating tumors
AcelRx announces handheld component of ARX-01
Adiana offers alternative to tubal ligation
Accumetrics announces GRAVITAS trial
AcelRx announces phase 2 for ARX-01
Kaiser's window to healthcare's future
KP Ventures invests in Torax Medical
Kaiser unveils new mobile health vehicle
Proteus ingestible microchip hits clinical trials
Kaiser joins healthy SF providers
KP honored as health IT leader
Covidien acquires Bacchus Vascular
Predictive Bio finds breast cancer marker
Arcxis secures series B financing
AcelRx shows positive results from clinical trial